Cannabis Manufacturers Should File DMFs To Help Drug Development: FDA

Cannabis products manufactured for non-FDA regulated purposes can also be used to develop pharmaceutical products. However, most cannabis products are manufactured using proprietary methods which the manufacturers would not share with pharmaceutical developers. In an email this week, FDA advised such manufacturers to file Drug Master Files (DMFs) that could be used to help drug … Read more

FDA Has Issued No Warning Letters For GMP Non-Compliance Since March

Since FDA effectively stopped auditing manufacturers six months ago due the pandemic, no company has been found to be non-compliant. Whether this means lax enforcement or more compliant manufacturing is open to debate. It should be noted that up until 10th March, FDA had conducted 231 inspections, and issued 7 Warning Letters in about 2 … Read more

Can You Use Self Experimentation Data for FDA Approval of Products?

Testing products on oneself to demonstrate their potential is as old as science itself. But self-experimentation maximizes concerns regarding the conflict of interest and bias in reported results making any reports anecdotal at best. So, can one use data from self-experiments to support formal additional clinical trials or even market approval? Self-experimentation is not illegal … Read more

FDA Has For Forever Tainted Plasma Treatment for COVID with Bad Politics

FDA’s decision this week to formally authorize COVID-19 convalescent plasma (CCP) as a treatment for COVID-19 was almost immediately panned almost universally as a politicized action by FDA. It did not help that the authorization was announced more like a campaign event than a regulatory milestone, with misleading statements, so much so that the FDA … Read more

FDA To Continue Remote Audits At Least Through The Rest of the Year

FDA published a guidance this week about its on-site inspection policies during the pandemic which all but confirms that it is not planning to conduct any foreign on-site inspections and few, if any, domestic on-site inspections, till at least the rest of the year and possible into the first quarter of next year. FDA will … Read more

Violators of Clinicaltrials.gov Requirements Given a Break by FDA

After years of hesitating to enforce the clinical trial reporting requirements, this week FDA released its guidance on penalties for non-compliance with clinicaltrials.gov posting rule. It satisfies the critics of the non-enforcement but at the same time gives a huge break to the current violators by wiping the slate clean and restarting the clock, in … Read more

Why is There so Little News About Drugs to Treat Covid-19?

While coronavirus vaccines have constantly been in the news, there is little noise about treatments. Vaccines cannot help those who are already infected and seriously ill, so, it should be surprising that there so little news about treatments. In fact, there are about 10 times as many Phase 2 and 3 treatment clinical trials for … Read more